Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-mggfc Total loading time: 0 Render date: 2025-02-23T13:07:37.854Z Has data issue: false hasContentIssue false

Quetiapine

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Quetiapine fumarate (2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid) is an atypical antipsychotic with a molecular weight of 883.1 and an empirical formula of (C21H25N3O2S)2,C4H4O4.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 377 - 390
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Klein, C, Prokhorov, T, Miniovich, A, Dobronevsky, E, Rabey, JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29(4): 215–219.CrossRefGoogle ScholarPubMed
Kyle, K, Bronstein, JM. Treatment of psychosis in Parkinson’s disease and dementia with Lewy bodies: a review. Parkinsonism Relat Disord 2020; 75: 55–62.CrossRefGoogle ScholarPubMed
Weintraub, D, Chiang, C, Kim, HM, Wilkinson, J, Marras, C, Stanislawski, B, Mamikonyan, E, Kales, HC. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016; 73(5): 535–541.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 15 August 2022 via www.medicinescomplete.com.Google Scholar
Arslan, ED, Demit, A, Yilmaz, F, Kavalci, C, Karakilic, E, Çelikel, E. Treatment of quetiapine overdose with intravenous lipid emulsion. Keio J Med 2013; 62(2): 53–57.CrossRefGoogle ScholarPubMed
Fernandez, HH, Okun, MS, Rodriguez, RL, Malaty, IA, Romrell, J, Sun, A, Wu, SS, Pillarisetty, S, Nyathappa, A, Eisenschenk, S. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009; 119(12): 2196–2205.CrossRefGoogle Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 15 August 2022 www.medicinescomplete.com.Google Scholar
Lizarraga, KJ, Fox, SH, Strafella, AP, Lang, AE. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med 2020; 36(1): 105–118.CrossRefGoogle ScholarPubMed
Ondo, WG, Tintner, R, Voung, KD, Lai, D, Ringholz, G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20(8): 958–963.CrossRefGoogle ScholarPubMed
Quetiapine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 15 August 2022 via www.medicinescomplete.com.Google Scholar
Quetiapine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 15 August 2022 via www.micromedexsolutions.com.Google Scholar
Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevskyu, E, Klein, C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22(3): 313–318.CrossRefGoogle ScholarPubMed
Reddy, S, Factor, SA, Molho, ES, Feustel, PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17(4): 676–681.CrossRefGoogle ScholarPubMed
Shotbolt, P, Samuel, M, Fox, C, David, AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat 2009; 5: 327–332.CrossRefGoogle ScholarPubMed
Shotbolt, P, Samuel, M, David, A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord 2010; 3(6): 339–350.CrossRefGoogle ScholarPubMed
Summary of product characteristics – quetiapine 100 mg film-coated tablets. Electronic Medicines Compendium: Quetiapine 100 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 15 August 2022 via www.medicines.org.uk.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Quetiapine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.040
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Quetiapine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.040
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Quetiapine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.040
Available formats
×